Previously, we have proved that PARP-inhibition could inhibit the transition of hypertensive cardiopathy to end-stage heart failure [6], but there is no data about the role of PAPR-inhibitors against the development of early consequences of hypertension. The gene discussed is PARP1; the disease is Hypertension.